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ABSTRACT
Interleukin-5 (IL-5) and granulocyte macrophage-
colony stimulating factor (GM-CSF) are important
cytokines for the proliferation, differentiation, and acti-
vation of myeloid lineages. The JAK/STAT pathway is
one of the signaling pathways implicated in mediating
biological responses induced by these cytokines. Previous
studies have demonstrated that these cytokines predomi-
nantly activate an 80 kDa STAT5 isoform in mature
granulocytes. To better understand the role of STAT pro-
teins during growth and differentiation of granulocytes,
we evaluated differentiation of human CD34+ hematopoi-
etic stem cells ex vivo toward eosinophils and neutrophils.
Bandshift experiments showed that in an early stage of
both differentiation pathways (14 days), the 94 kDa
STAT5B protein was activated by both IL-5 (eosino-
phil lineage) and GM-CSF (neutrophil lineage). How-
ever, during maturation of both lineages (days 21 and
28), increased expression of a functionally distinct 80
kDa STAT5 isoform was observed, resulting in het-
erodimer DNA-binding complexes containing both the
94 and 80 kDa STAT5 proteins. The finding that
functionally distinct isoforms of STAT5 are activated
during the early and late differentiation stages of
granulocytes suggests that they might be involved in
regulating different biological functions in these cells.
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INTRODUCTION
Signal transducers and activators of transcription (STAT)
proteins are a recently identified class of transcription factors
involved in mediating many cytokine-induced responses [1].
These proteins reside in a latent form in the cytoplasm and
become phosphorylated by the Janus kinase (JAK) family of
tyrosine kinases following cytokine-receptor activation.
Once phosphorylated, STAT proteins dimerize, translocate
to the nucleus, and bind specific DNA sequences present in
promoter regions to regulate gene transcription [2, 3]. 
The STAT proteins may play an important role in
hematopoiesis. Recent persuasive data suggest a role for
STAT proteins in both proliferation and differentiation
processes. For example, STAT4 is important for both the
proliferation and differentiation of Th1 lymphocytes [4, 5],
and STAT6 for the proliferation and differentiation of Th2
lymphocytes [6-8]. Furthermore, it has been shown that
STAT3 plays a role in the differentiation of the myeloid M1
cell line into macrophages [9]. Constitutive activation of
STAT5 in T-cells transformed by the HTLV-1 leukemia
virus [10] and in chronic myelogenous leukemia (CML) cells
transformed with BCR-ABL [11] suggests that activation of
STAT5 correlates with mitogenic responses.
Of the presently known STAT proteins, STAT1a , STAT3
and several isoforms of STAT5 have been reported to be acti-
vated by the cytokines interleukin-3 (IL-3), IL-5, and GM-
CSF [12-17]. Of this cytokine family, the activity of IL-5 is
restricted to the differentiation and subsequent activation of
eosinophils and basophils [18-21]. In contrast, IL-3 and GM-
CSF have broader and overlapping roles in the growth, dif-
ferentiation, and activation of multiple myeloid lineages [22]. 
Despite recent progress in unraveling the signaling
events activated by IL-5 and GM-CSF, the mechanism by
which these cytokines utilize the JAK-STAT signaling to
accomplish their distinct spectrum of biological activities
remains largely unknown. We have recently shown that in
contrast to the activation of full-length STAT5 proteins in
myeloid cell lines, IL-5 and GM-CSF activated a carboxyl-
truncated p80 STAT5 protein in human granulocytes
(Caldenhoven et al., submitted). These observations
prompted us to study the activation of STAT proteins by
IL-5 and GM-CSF during the differentiation of CD34+
hematopoietic stem cells (HSCs) into eosinophils or neu-
trophils. HSCs expressing the CD34 antigen (CD34+ cells)
mainly reside in the bone marrow and are capable of exten-
sive self-renewal and of differentiation into committed
progenitors of the different myeloid and lymphoid com-
partments [23]. The growth, differentiation and survival of
hematopoietic cells is at least in part regulated by a net-
work of hematopoietic growth factors (HGFs) [22].
Whereas cytokines such as IL-3, GM-CSF, stem cell factor
(SCF), fms-like tyrosine kinase-3 (Flt-3) ligand, and IL-6
are early and multilineage growth factors [24-26], terminal
differentiation is accomplished by unilineage cytokines such
as G-CSF (neutrophil lineage), erythropoietin (erythrocyte
lineage), thrombopoietin (megakaryocyte lineage), and IL-5
(eosinophil lineage) [21, 22]. 
In this report we have explored the activation of STAT
proteins in CD34+ HSC isolated from cord blood (CB), and
induced in liquid suspension culture to gradual differentiation
along the neutrophil (G-CSF) and eosinophil lineage (IL-5). 
MATERIALS AND METHODS
Cell Culture and Reagents
Blood was obtained from healthy volunteers from the
bloodbank, Utrecht, The Netherlands. Human polymor-
phonuclear neutrophils (PMNs) were isolated from the
buffy coat of 500 ml blood anticoagulated with 0.4%
trisodium citrate (pH 7.4) as previously described [27].
Eosinophils were subsequently isolated by the method
described by Hansel et al. [28]. Human interleukin-5
(huIL-5) was a kind gift of Dr. D. Fattah (Glaxo Wellcome
group research; Stevenage, UK). Human GM-CSF and
huIL-3 were obtained from Genzyme (Cambridge, MA),
and human G-CSF was obtained from Amgen (Thousand
Oaks, CA). Human fms-like tyrosine kinase-3 (FLT-3)
ligand and SCF were obtained from Pepro Tech (Rocky
Hill, NJ).
Isolation of Human CD34+ Stem Cells by Magnetic Cell Sorting
(MiniMacs)
Cord blood was collected in 50 ml tubes containing
trisodium citrate (pH 7.4, 0.4% final concentration). Blood was
then diluted twofold with Iscove’s modified Dulbecco’s
medium (IMDM) (GIBCO; Paisley, UK) containing 0.4%
trisodium citrate. Mononuclear cells (MNC) were isolated from
umbilical cord blood cell (CBMC) samples by density centrifu-
gation (2,000 rpm, 20 min) over Ficoll-Hypaque solution (den-
sity 1.077 g/ml). The resulting MNC were subjected to
hypotonic lysis of red cells. MNC were resuspended at 108 per
150 µl in cold PBE buffer (phosphate buffered saline [PBS],
0.5% bovine serum albumin [BSA], 5mM EDTA). Blocking
reagent (50 µl) and the antibody reagent from the CD34 isola-
tion kit (50 µl), (MACS, Miltenyi Biotec; Bergisch Gladbach,
Germany) were added simultaneously to the cell suspension,
mixed well and incubated for 15 min at 4°C on a rotating wheel.
After incubation, cells were washed with PBE, resuspended in
200 µl PBE, and 50 µl of the colloidal suspension of submicro-
scopic magnetic beads were added to the cells, mixed and incu-
bated for 15 min at 4°C on a rotating wheel. The cells were
washed carefully with PBE, resuspended in 0.5 ml PBE and
applied to the prefilled column which was placed in a magnetic
field. Cells which did not bind CD34 antibody passed through
the column while CD34+ cells were retained. The CD34+ cells
were eluted by removing the column from the magnetic field
and flushing the column with PBE. The entire procedure was
performed according to manufacturer’s instructions. 
Culturing and Differentiation of CD34+ Cells
Between 2 · 105 and 5 · 105 CD34+ cells/ml were cultured
in 24-well plates in IMDM. The medium was supplemented
with 10% fetal calf solution (FCS), SCF (100 ng/ml), FLT-3
ligand (100 ng/ml), IL-3 (0.1 nmol/l), GM-CSF (0.1 nmol/l),
and IL-5 (0.1 nmol/l) for eosinophil differentiation or G-CSF
(30 ng/ml) for neutrophil differentiation. After three days, cells
were counted and resuspended in IMDM containing IL-3 and
IL-5 (eosinophils) or IL-3 and G-CSF (neutrophils). Cells
were maintained at a density between 0.5 · 106 and 3 · 106
cells. From day 21, IL-3 was also omitted from the media.
Growth and viability were determined by light microscopic
evaluation with 1% trypan blue exclusion. Viability remained
>95% throughout the 28-day experiment period.
Antibodies and Synthetic Oligonucleotides
The polyclonal antibodies directed against STAT5 (N-
20, aa5-24), and STAT5B (C-17, aa711-727), were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). The fol-
lowing oligonucleotides were used in this study (only the
upper strands are shown below): b -casein STAT5 binding
site (5 ¢ -AGCTTAGAT TTCTAGGAATTCAAATCA-3¢ )
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and human ICAM-1 IRE (5¢ -AGCTTAGTT
TCCGGGAAAGCAC-3¢ ).
Gel Retardation Assay
Twenty-four hours prior to nuclear extract preparation,
cells were washed three times and resuspended in fresh
IMDM (2 · 106 cells per ml) without any cytokines.
Nuclear extracts were prepared from unstimulated cells or
cells stimulated with either IL-5 (0.1 nmol/l) or GM-CSF
(0.1 nmol/l) for 15 min following a previously described
procedure [29]. Oligonucleotides were labeled by filling in
the cohesive ends with [a -32P]dCTP using Klenow frag-
ment of DNA polymerase I. Gel retardation assays were
carried out according to published procedures with slight
modifications [30]. Briefly, nuclear extracts (10 µg) were
incubated in a final volume of 20 µl, containing 10 mM
HEPES, pH 7.8, 50 mM KCL, 1 mM EDTA, 5 mM MgCl2,
10% (v/v) glycerol, 5 mM dithiothreitol, 2 µg poly(dI-dC)
(Pharmacia; Roosendaal, The Netherlands), 20 µg BSA and
1.0 ng of 32P-labeled oligonucleotide for 20 min at room tem-
perature. Subsequently, samples were electrophorized for
three to four hours on 5% nondenaturing polyacrylamide gels
at room temperature. Supershift analyses were performed by
pre-incubating 10 µg of nuclear extract with 1 µg of anti-
STAT5 antibody for 30 min on ice prior to the addition of
the binding buffer and 32P-labeled probe.
Whole Cell Extracts and Western Blotting
Whole cell extracts were prepared by lysing the cells
directly in boiling Laemmli sample buffer. Protein samples
were separated on 8% SDS polyacrylamide gels, and electro-
transferred to Immobilon-P membranes (Millipore; Bedford,
MA). Ponceau S staining was used to check for variations in
protein loading, which were never higher than 1.5-fold
between different lanes. Membranes were blocked in TBST-
buffer (150 mmol/l NaCl, 10 mmol/l Tris pH 8.0, 0.3%
Tween 20) containing 5% BSA for 30 min and probed with
a polyclonal antibody against human STAT5 (aa 5-24) for
one h. After three washes with TBST the membranes were
incubated for one hour with either antiperoxidase-conjugated
swine-anti-rabbit antibodies (DAKO; Golstrup, Denmark),
followed by five washes with TBST. Proteins were visual-
ized with enhanced chemiluminescence ([ECL], Amersham,
Buckinghamshire, UK).
RESULTS AND DISCUSSION
Ex Vivo Expansion and Differentiation of Isolated CD34+
Stem Cells
CD34+ hematopoietic stem cells were enriched from
cord blood by using an immunomagnetic system as described
in Materials and Methods. To induce ex vivo expansion,
CD34+ progenitor cells were cultured in the presence of
human SCF, FLT3-ligand, IL-3, and GM-CSF and with
either IL-5 or G-CSF to induce eosinophil or neutrophil mat-
uration, respectively. After three days, SCF, FLT3-ligand
and GM-CSF were omitted from the media, while after 21
days IL-3 was also omitted. The number of cells in culture
and their morphological features were monitored from day 0
to day 28. The CD34+ cell population (purity 95%) consists
of small cells with very little cytoplasm (Fig. 1A). After three
days of culture in the presence of SCF, FLT3-ligand, GM-
CSF, and with either IL-5 or G-CSF, cell numbers increased
two- to fourfold (Fig. 1B), and the morphology and size of
the cells changed dramatically (Fig. 1A). Further culture to
day 28 with the addition of IL-3 and IL-5 or IL-3 and G-CSF
resulted in phenotypic maturation toward mature eosinophils
or neutrophils, respectively (Fig. 1A). The growth of human
CD34+ cells for 28 days resulted in a 300-fold increase in cell
number for the eosinophil lineage, and a 500-fold increase
for the neutrophil lineage (Fig. 1B). Although at three, seven
and 14 days the cultures were heterogeneous, eosinophilic
and neutrophilic cells were clearly observed in increasing
numbers. After 28 days, the cultures with G-CSF contained
about 90% neutrophils, while the IL-5-treated cultures con-
tained 90% eosinophils as judged by microscopic analysis
(data not shown).
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Figure 1. Morphological characterization and expansion of CD34+ cells
undergoing eosinophilic or neutrophilic differentiation. A) Isolated CD34+
cells from cord blood were cultured in the presence of SCF (100 ng/ml),
FLT3-ligand (100 ng/ml), IL-3 (0.1 nmol/l), GM-CSF (0.1 nmol/l), and either
IL-5 (0.1 nmol/l) for eosinophil differentiation or G-CSF (30 ng/ml) for neu-
trophil differentiation (see Materials and Methods section for details). At the
indicated times, cells were cytocentrifuged and stained with May-Grünwald-
Giemsa solution (original magnification · 1,000). Pictures are not represen-
tative for all the cells at a given timepoint (see text for details). B) At the
indicated times, cells were counted, and results are expressed as fold increase
in cell numbers compared with day 0.
Activation of Functionally Distinct STAT5 Proteins 
by IL-5 and GM-CSF During Eosinophil and Neutrophil
Differentiation of CD34+ Cells
We and others have recently shown that several different
STAT5 isoforms are activated by IL-3, IL-5, and GM-CSF in
distinct populations of cells [15-17] (Caldenhoven et al., sub-
mitted). Moreover, it was shown that activation of these func-
tionally distinct STAT5 isoforms is correlated with the
differentiation stage of the cell [15]. We used our ex vivo
CD34+ stem cell differentiation system to analyze STAT acti-
vation by IL-5 and GM-CSF during eosinophil and neutrophil
development. Since the other cytokines used in our differenti-
ating culture system (e.g., IL-3 and G-CSF) also affect STAT
proteins, the cells were washed three times and resuspended in
fresh IMDM (2 · 106 cells per ml) without any cytokines 24 h
prior to nuclear extract preparation. Cells were then stimulated
with IL-5 (eosinophils) or GM-CSF (neutrophils) for 15 min,
after which nuclear extracts were prepared and STAT activa-
tion was analyzed in a bandshift assay using the 32P-labeled
b -casein element as a probe. As can be seen in Figure 2, IL-5
and GM-CSF induce the activation of a DNA-protein complex
in cells of different developmental stages (day 14, day 28, and
mature cells) of both the eosinophil and neutrophil lineages.
However, we observed along the maturation of both lineages
an increase in migration of the DNA-protein complexes, indi-
cating that there might be differences in the components in
these complexes (Fig. 2). Although the cells at day 14 are still
somewhat heterogeneous, it is likely that the IL-5 effects
observed represent eosinophilic cells, since we have never
observed basophils in our cultures, which are the only other
human cells expressing a functional IL-5 receptor. Similarly,
the effects of GM-CSF in early (14 day) neutrophil cultures
are likely to represent neutrophilic cells, although we cannot
rule out that some pre-eosinophilic or monocytic cells con-
tribute to the observed GM-CSF-induced STAT5 band.
However, since the cultures at day 28 contain 90% mature
granulocytes, here we can be quite sure that the effects
observed with IL-5 and GM-CSF represent eosinophils and
neutrophils, respectively.
To evaluate whether the observed differences in migra-
tion are due to the activation of different STAT5 isoforms,
we pre-incubated these nuclear extracts with an amino-ter-
minal (N) anti-STAT5 antibody (aa 5-24) recognizing all
STAT5 isoforms and a carboxyl-terminal (C) anti-STAT5B
antibody (aa 750-769) recognizing only full-length STAT5B.
To distinguish the differences between these and the DNA-
protein complexes, we performed a long-run gel retardation
assay (16 h). As can be seen in Figure 3A, the DNA-protein
complex activated by IL-5 and GM-CSF in cells of both lin-
eages after a 14-day culture was supershifted by both the
C-and N-terminal antibodies indicating that the full-length
94 kDa STAT5B protein is activated (lanes 1-3 and 10-13).
In contrast, in mature eosinophils and neutrophils a faster
migrating DNA-protein complex was activated by IL-5 and
GM-CSF which was only recognized by the N-terminal anti-
STAT5 antibody (lanes 7-9 and 16-18). This observation is
consistent with our previous findings that a carboxyl-termi-
nal truncated 80 kDa STAT5 protein is activated in these
cells (Caldenhoven et al., submitted). Surprisingly, since we
performed a long-run gel retardation assay, we observed an
additional intermediate DNA-protein complex in neutrophils
(lane 16). This intermediate DNA-protein complex is likely to
be a p80/p94 heterodimer since it is recognized by the N-ter-
minal STAT5 antibody (lane 17 and 18). The activation of
this intermediate complex by IL-5 and GM-CSF containing a
p80/p94 STAT5 heterodimer was also observed in cells after
a 28-day culture of both the eosinophil and neutrophil lin-
eages (lanes 4 and 13). However, in these cells additional to
the intermediate DNA-protein complex a slower migrating
DNA-protein complex is activated which is a full-length
STAT5 homodimer since it is supershifted by both antibodies
(lanes 6, 7 and 14, 15). 
We have recently shown that the long and short STAT5
proteins exhibit different binding specificities (Caldenhoven
et al., submitted). Therefore, we analyzed the different
STAT5 complexes for binding to the ICAM-1 IRE. As shown
in Figure 3B, the full-length STAT5 homodimer which is
activated on day 14 was not able to bind to the ICAM-1 IRE,
whereas the heterodimer p94/p80 (day 28) and the p80 homo-
dimer (mature cells) did bind to this sequence. In addition to
the difference in DNA-binding specificity, it is also suggested
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Figure 2. Activation of DNA-protein complexes by IL-5 or GM-CSF in dif-
ferentiating granulocytes. Nuclear extracts were prepared from unstimulated
and IL-5- or GM-CSF-stimulated (15 min) differentiating CD34+ cells into
eosinophils or neutrophils at different time points as indicated (day 14, 21, 28,
and mature (mat) cells). Twenty-four h before stimulation, cells were cytokine-
starved (see Materials and Methods for details). Nuclear extracts were evaluated
for STAT binding to a 32P-labeled b -casein element in a bandshift assay. The pat-
tern of DNA-protein complexes activated by IL-5 or GM-CSF is altered during
granulocyte differentiation.
that carboxyl-truncated STAT proteins are transcriptionally
inactive. This has been shown not only for the naturally car-
boxyl-truncated STAT1b and STAT3b proteins [31, 32], but
also for carboxyl-truncated STAT5 proteins generated by
polymerase chain reaction [33, 34]. Furthermore, it has been
shown that in FdTrk cells in which only the truncated p80
STAT5 protein is activated, IL-3 fails to induce several imme-
diate early genes, including CIS, Pim-1 OSM and c-fos, sug-
gesting that p80 STAT5 is transcriptionally inactive [17].
Taken together, this might indicate that by generation of func-
tionally distinct STAT5 proteins during granulocyte differen-
tiation, different genes might be affected, potentially eliciting
different biological responses.
Expression of STAT5 Proteins in CD34+ Stem Cells
Undergoing Eosinophil or Neutrophil Differentiation
To determine the expression levels of the short and long
STAT5 isoforms during CD34+ differentiation, we prepared
whole cell extracts from cells (5.105 per lane) at different time
points during eosinophil or neutrophil differentiation. These
whole cell lysates were subjected to SDS-PAGE, and analyzed
by Western blotting with the N-terminal anti-STAT5 antibody
recognizing both full-length and carboxyl-truncated STAT5
proteins. Our results show that CD34+ hematopoietic stem
cells express mainly the long forms (96/94 kDa) of STAT5
(Fig. 4, lane 4). Interestingly, during eosinophil and neutrophil
differentiation increased expression of the 80 kDa STAT5 is
observed (lanes 1-3 and 5-7). The expression of the 80 kDa
STAT5 protein in the neutrophil lineage was somewhat higher
than in the eosinophil lineage. Although there was some vari-
ation in the amount of p80 and the time course of p80 genera-
tion between different experiments (probably due to donor
variation), enhanced expression of p80 was consistently
observed during both eosinophil and neutrophil differentiation
(data not shown).
Taken together, our results show that during the differ-
entiation of CD34+ stem cells into mature eosinophils or
neutrophils, the p80 STAT5 protein is upregulated and subse-
quently activated by IL-5 and GM-CSF. Recently, it has been
suggested that the carboxyl-truncated STAT5 isoforms are
generated by a unique protein-processing event from the full-
length STAT5 proteins by a specific protease [17]. Our obser-
vation that during granulocyte differentiation the expression of
the carboxyl-truncated STAT5 protein is increased suggests
that this protease might be differentially regulated in granulo-
cytes. In contrast to our observations, Azam et al. [15, 17] have
reported that the carboxyl-terminal truncated STAT5 protein is
activated in immature murine myeloid cells and the long forms
of STAT5 in mature myeloid cells. An explanation for this dis-
crepancy could be that their studies were done in murine
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Figure 3. IL-5 and GM-CSF
induces functionally distinct
STAT5 isoforms during granu-
locyte differentiation. A) Nuclear
extracts from IL-5 or GM-CSF-
stimulated differentiating eosino-
phils or neutrophils (day 14, 28,
and mature cells), were pre-incu-
bated with either an amino-termi-
nal (N) anti-STAT5 (aa 5-24)
antibody (lanes 2, 5, 8, 11, 14, and
17) or a carboxyl-terminal (C)
anti-STAT5B (aa 750-769) anti-
body (lanes 3, 6, 9, 12, 15, and
18). Nuclear extracts were analyzed in a bandshift assay with a 32P-labeled b -casein element as a probe. B) Nuclear extracts from IL-5 or
GM-CSF stimulated differentiating eosinophils or neutrophils (day 14, 21, 28, and mature [M] cells) were analyzed for binding to the
ICAM-1 IRE in a bandshift assay. We conclude from these results that during differentiation IL-5 and GM-CSF activate functionally
distinct STAT5 isoforms.
Figure 4. Expression of STAT5 isoforms during eosinophil and
neutrophil differentiation. Whole cell extracts were prepared in a
boiling sample buffer of cells from different stages of CD34+ stem
cells (5 · 105 cells per lane) undergoing either eosinophil or neu-
trophil differentiation. Proteins were separated through an 8%
polyacrylamide gel and blotted onto nylon membranes. The filter
was probed with the N-terminal anti-STAT5 antibody (aa 5-24).
The carboxyl-terminal truncated p80 STAT5 protein is upregulated
during granulocyte differentiation.
myeloid cell lines and not in human primary cells.
Although the functional relevance of the switch between
p96 and p80 STAT5 remains to be determined, the gener-
ation of functionally distinct STAT5 isoforms during granu-
locyte differentiation might well be involved in the
regulation of distinct biological responses elicited by these
cytokines during granulopoiesis, such as proliferation versus
differentiation/activation.
SUMMARY AND CONCLUSIONS
While IL-5 and GM-CSF stimulate the proliferation of
early myeloid progenitors, they are also involved in the ter-
minal differentiation and maturation of granulocytes. We
have shown that IL-5 and GM-CSF activate wild-type
STAT5 in immature human myeloid cells cultured from
CD34+ stem cells. By contrast, these cytokines induce the
activation of a C-terminally truncated p80 STAT5 protein
during later stages of eosinophil and neutrophil differentia-
tion and in mature peripheral granulocytes. Since the p80
STAT5 has different functional properties compared with
wild-type STAT5, the switch between these proteins during
granulocyte differentiation might well contribute to the dif-
ferent responses elicited by IL-5 and GM-CSF in immature
compared to mature granulocytes.
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